Johnson & Johnson has claimed FDA approval for new formulation of its blockbuster multiple myeloma drug Darzalex that cuts its dosing time to just a few minutes from hours and could help it fend ...

J&J reported overall revenues up 4.3% to $22.4 billion in the second quarter, fuelled by growth for blood cancer therapy Darzalex (daratumumab) and particularly subcutaneous version Darzalex ...

DelveInsight’s “Sickle Cell Disease Pipeline Insights 2025” report provides comprehensive insights about 55+ companies and 60+ drugs in the Sickle Cell Disease Competitive landscape. It ...

“Preliminary results are encouraging, with 100 percent of patients achieving the primary endpoint of successful CD34+ stem cell mobilization, including patients previously treated with ...

ELREXFIO: Initial safety and efficacy results from Part 1 of the ongoing MagnetisMM-6 study of ELREXFIO in combination with daratumumab and lenalidomide in patients with newly diagnosed MM that ...

Gut microbiome analysis of patients with multiple myeloma receiving idecabtagene vicleucel (ide-cel) therapy revealed specific bacterial species linked to treatment response and toxicity outcomes ...

Methods and Results: Patients undergoing subcutaneous device implantation were randomized to one of two groups. The control group received standard instructions, whereas the exercise group was ...

Ozempic (semaglutide) and Wegovy (semaglutide) are prescription drugs that may be used to help with long-term weight loss. But only Wegovy is FDA approved for this use. Both drugs are approved for ...

Sleep, light, and temperature adjustments were the most feasible in-home interventions to decrease agitation in patients with dementia. A novel monitoring and analysis tool has identified ...